Literature DB >> 2889724

Clonazepam: new uses and potential problems.

L S Cohen1, J F Rosenbaum.   

Abstract

Clonazepam is a high-potency benzodiazepine labeled for use as an anticonvulsant. Increasingly, clonazepam has been used in the treatment of a variety of psychiatric disorders. The authors discuss its potential clinical applications, including (1) use as an adjunct to neuroleptics for treating psychosis, (2) management of specific psychotropic side effects, (3) alternative treatment for certain pain syndromes, and (4) a primary treatment for severe agitation, atypical psychosis, and anxiety disorders. Apparent treatment-emergent side effects including depression, disinhibition, and sexual dysfunction are also discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2889724

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

Review 1.  A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.

Authors:  L L Carpenter; C J McDougle; C N Epperson; L H Price
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 2.  Pharmacological treatment of psychotic agitation.

Authors:  Glenn W Currier; Adam Trenton
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 3.  Diagnosis and treatment of agoraphobia with panic disorder.

Authors:  Giulio Perugi; Franco Frare; Cristina Toni
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Sleep-Related Eating Disorder (SRED): Paradoxical Effect of Clonazepam.

Authors:  Debabrata Ghosh; Abigail M Petrecca; Abdul Latif Khuhro
Journal:  J Clin Sleep Med       Date:  2018-07-15       Impact factor: 4.062

5.  Influence of sildenafil on the anticonvulsant action of selected antiepileptic drugs against pentylenetetrazole-induced clonic seizures in mice.

Authors:  Dorota Nieoczym; Katarzyna Socała; Jarogniew J Łuszczki; Stanisław J Czuczwar; Piotr Wlaz
Journal:  J Neural Transm (Vienna)       Date:  2012-08       Impact factor: 3.575

6.  Population pharmacokinetics of clonazepam in saliva and plasma: Steps towards noninvasive pharmacokinetic studies in vulnerable populations.

Authors:  Matthijs D Kruizinga; Rob G J A Zuiker; Kirsten R Bergmann; Annelies C Egas; Adam F Cohen; Gijs W E Santen; Michiel J van Esdonk
Journal:  Br J Clin Pharmacol       Date:  2021-12-09       Impact factor: 3.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.